A B S T R A C T During the third trimester of
INTRODUCTION
In 1968, Sj6vall and Sj6vall (1) reported the finding of large quantities of 5a-pregnane-3a,20a,21-triol as the monosulfate in plasma obtained from pregnant women in the third trimester. Since then, several groups of investigators (2-7) including ourselves (8) have found that the levels ofdeoxycorticosterone (DOC)1 in plasma of women late in pregnancy are 4-50 times those found in nonpregnant women and men. The mechanism(s) leading to the elevated DOC levels in the plasma of women late in pregnancy, however, is not established. The increased plasma levels of DOC appear to be due to increased production in that the production rate of DOC in one pregnant subject was 8.1 mg/24 h (2). Brown and Strott (9) found that the intravenous infusion of angiotensin II was not accompanied by an increase in plasma DOC concentrations; thus, it is unlikely that the pregnancy-induced increase in the levels of angiotensin II in plasma brings about an increase in adrenal secretion of DOC.
Most investigators have surmised that the high level of DOC in the maternal circulation is the result of the transfer to the mother of DOC produced in the fetus or fetal-placental unit. Their view was based on the findings that the levels of DOC and DOC-sulfate in umbilical cord plasma were higher than those in maternal plasma (2, 6, 10, 11) and that within 16-24 h after delivery, maternal plasma levels of DOC fell to levels found in nonpregnant women and men (2, 6) . Importantly, it was also found that treatment of nearterm pregnant women with dexamethasone or ACTH did not lead to significant changes in plasma DOC concentrations (2, 4, 5, 7, 12) . However in pregnant women near term, urinary 3a,21-dihydroxy-5,8-pregnan-20-one (tetrahydro-DOC) excretion was increased by ACTH-treatment (12) . Nolten et al. (7) concluded that these results could be explained as follows: ACTH-treatment of pregnant women was associated with an increase in plasma cortisol concentration. They believed that DOC secretion was also increased after ACTH treatment but that the ACTH-induced increase in cortisol levels in plasma brought about a proportionate displacement of DOC from corticosteroid-binding globulin, resulting in an elevation in free DOC but little change in the total concentration of DOC in plasma.
We considered an alternate hypothesis to explain the finding of high levels of DOC in plasma of women late in pregnancy, viz., that DOC may be derived, in part, from the 21-hydroxylation of circulating progesterone. There are many precedents for the formation of biologically active steroid hormones from circulating precursors, e.g., the placental formation of 17,8-estradiol from circulating maternal and fetal dehydroisoandrosterone sulfate (13) (14) (15) , the extraglandular formation of testosterone (16) and estrone (17) from plasma androstenedione, as well as the formation of 17,13-estradiol from plasma testosterone (18) and from plasma estrone (19) .
During late human pregnancy, 250 mg or more of progesterone enter the maternal circulation each day (20, 21) . Thus, even a small fractional conversion of maternal plasma progesterone to DOC could account for considerable DOC production compared to that normally secreted by the adrenal cortex. Moreover, the conversion of circulating progesterone to DOC would provide an explanation for the finding that neither dexamethasone nor ACTH treatment of pregnant women was followed by significant alterations in the levels of DOC in maternal plasma. To test the possibility that plasma progesterone is converted to DOC, we estimated the fractional conversion of plasma progesterone to DOC by the "urinary method." The transfer constant of conversion ofplasma progesterone to DOC was computed from the relationship between the 3H:14C ratio of the infused tracers, following study was conducted. 500 ml of blood were withdrawn from a 45-yr-old nonpregnant woman volunteer (subject S-14); the plasma (300 ml) was separated by plasmapheresis, and the erythrocytes were infused back into this woman before commencement of the study. Nonradiolabeled progesterone was dissolved in the plasma as described (23) to give a final concentration of 123 ug progesterone/ml plasma. The tracers, [3H]P (-190 ,Ci) plus [14C]DOC (-1.0
,uCi), were infused intravenously into this subject at a constant rate for 6 h. After 3 h of radiolabeled steroid tracer infusion, a 50-ml sample of blood was withdrawn from the contralateral arm, and a second infusion consisting ofher plasma containing nonradiolabeled progesterone was begun at a rate to deliver 2.5 mg progesterone/h; an amount similar to the estimated production rate of progesterone in early pregnancy. After 1 h of progesterone infusion, another 50-ml blood sample was obtained, and the rate of infusion of nonradiolabeled progesterone was increased to 10 mg/h; an amount similar to the estimated production rate of progesterone in the early third trimester of pregnancy. After 1 h, another 50-ml blood sample was obtained, and the rate of infusion of nonradiolabeled progesterone was increased to 14 mg/h; an amount similar to the estimated production rate of progesterone in pregnant women near term. This rate of progesterone infusion was continued for 1 h, a final 50-ml blood sample was obtainen, and all infusions were discontinued. Urine was collected for 72 h. The experimental design employed in this study is illustrated in Fig. 1 Standards and unknowns (the equivalent of 25% of the plasma extract) were incubated in duplicate with antiserum (diluted 1:5,000 in assay buffer) and 5,000 cpm [3H]DOC. After an overnight incubation at 4°C, dextran-coated charcoal suspension (0.2 ml) was added. The tubes were agitated and incubated for 10 min at 4°C, and then centrifuged at 2,000 rpm for 10 min at 4°C. The supernatant fluid (containing antibody-bound steroid) was assayed for radioactivity in a li(uid scintillation spectrometer. The concentration of DOC in uinknown samples was computed and the values were corrected for procedural losses by the use of the internal recovery standard. The sensitivity of the method is 6 pg and the least amount of DOC detectable in the assay method, assuming 100% recovery of DOC (luring extraction and chromatography, is 24 pg DOC/ml plassma. To evaluate the accuracy of the method, known quantities of nonradiolabeled DOC (100, 200, 300, or 400 pg) were added to aliquots (in triplicate) of a plasma pool, containing 103 pg DOC/ml, which were then assayed for DOC as described above. The differences in DOC concentrations between the plasma pool with no DOC added and that in samples to which DOC was added were 99, 197, 295, and 393 pg, respectively. Within assay and between assay variations for the DOC radioimmunoassay procedure were 7 and 17%, respectively. was remarkably constant in the two persons studied on separate occasions. Therefore the rate of DOC formation from plasma progesterone was directly proportional to the plasma progesterone level.
RESULTS
In two adrenalectomized women the [p]BDoc was 0.003 and 0.007, values which are within the range for subjects with normal adrenal function. Based on these results and those obtained in a man with Cushing syndrome, in whom the [p] P-DOC was only 0.002, it seems likely that little or none of the plasma progesterone was converted to DOC in the adrenal cortex. This conclusion can be reached through another line of deduction. If one assumes that plasma flow to the adrenal cortex were 1 ml min-' g-1 tissue (27) and that the weight of the two adrenal glands were 10 g, the plasma CG9-steroids, testosterone formation from circulating andostenedione as well as 5a-dihydrotestosterone production from plasma testosterone (13) (14) (15) (16) (17) (18) (19) . To our knowledge this is the first demonstration of the formation of the potent mineralocorticosteroid, DOC, from circulating precursors in adults. Bird et al. (31) found radiolabeled DOC-sulfate in adrenal tissue after infusing radiolabeled progesterone to previable human abortuses and concluded that the DOC-sulfate was formed from circulating progesterone in the fetal adrenal gland. Other investigators have demonstrated 21-hydroxylase activity in incubations of fetal testicular (32) tissue and human ovarian (33) tissue that was believed to be abnormal. However, it seems unlikely that the conversion of plasma progesterone to DOC observed in the present study occurred in the gonads of these subjects. As in the case of the adrenal cortex, near complete extraction and 21-hydroxylation of circulating progesterone by the gonads would have been required to account for the estimated MCR-PDoc.
The finding of wide variations in [p]P-DOc among the subjects of this study, while the [p]P--DIc in the same subject remained fixed, is of considerable interest. Ordinarily the fractional conversion of a steroid prehormone to a product hormone is similar among normal persons. For example, the fractional conversion of plasma androstenedione to estrone (17, 19) and to plasma testosterone (16, 19) varies little among normal young adults. Similarly the transfer constant of con-version of plasma testosterone to 17,8-estradiol is similar among normal men (18, 19) and among nonpregnant women (18, 19) . This was not the case for the fractional conversion of plasma progesterone to DOC.
Indeed, a 10-fold variation in the [p]LBU' was found among normal persons. If the DOC derived from plasma progesterone were physiologically important, it follows that a much greater impact of such conversion could exist in persons with greater capacity to convert plasma progesterone to DOC. This might be especially important when high levels of plasma progesterone are present, e.g., during the luteal phase of the ovarian cycle and during pregnancy. In women late in pregnancy, in whom 250 mg progesterone are produced each day, the amount of DOC derived from plasma progesterone could vary from 0. were more similar. Based on these observations, we speculated that the relationship between the conversion of progesterone to DOC in plasma and the fractional conver-sion computed from the 3H:14C ratio of uirinary tetrahydro-DOC might be influenced by the intracellular conicentration of progesterone. This seemedl to be an attractive hypothesis since the [p]PDI)(C was not alteredl by changes in plasma progesterone concentration ancd therefore, the amount of 21-hydroxylase activity in the cellular site(s) of DOC formation was not satuirated even during pregnancy. Rather, it was postulated that the amount of DOC formed from plasma progesterone that entered blood could be limited by the in situ conversion of DOC to tetrahydro-DOC. In turn, the rate of tetrahydro-DOC formation in the cellular site(s) of conversion of progesterone to DOC could be influenced by competition of intracellular progesterone and DOC for the 5,8- Other investigators have concluded that the high levels of DOC in the plasma of women late in pregnancy are due to transfer to the mother of DOC formed in the fetus. The basis for this conclusion was the finding of higher levels of DOC in the umbilical cord plasma of the newborn than in the mother together with the observation that the levels of DOC in maternal plasma were not altered by ACTH or dexamethasone treatment.
However, Brown and co-workers (2) found that the mean plasma level of DOC in umbilical arterial plasma was 1.92 ng/ml, whereas that of umbilical venous plasma was 1.71 ng/ml. Therefore 
